Blackstone and Alnylam Pharmaceuticals closed the R&D funding component of the companies’ previously announced $2 billion strategic financing collaboration to accelerate therapeutics for cardiovascular disease.
The $150 million investment is from Blackstone Life Sciences, which last month announced its $4.6 billion fundraise that included deals with Alnylam, Reata Pharmaceuticals and Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.Continue Reading
